Indian pharma and healthcare firms face a mixed March quarter. While hospitals anticipate steady growth, generic drugmakers grapple with lo...

The Indian subsidiary of the UK-based GSK PLC had urged the court to cancel the mark used by the local company in pharmaceutical and medici...

In today's trade, shares of SBI Life, Trent, Tata Investment, HCL Tech, Suzlon Energy among others will be in focus due to various news dev...

Aurobindo Pharma has announced an ₹800-crore buyback at ₹1,475 per share, with April 17, 2026 set as the record date—meaning investors must...

The land parcel, expected to fetch about ₹3,400 crore for AstraZeneca Pharma India, has drawn interest from developers including the Sattva...

Aurobindo Pharma stock is performing well. Sales in Europe are improving. New products are launching in the US. The company is also develop...

India's Auro Realty, the real estate arm of Aurobindo Group which also owns drugmaker Aurobindo Pharma, is planning to raise 20 billion rup...

Kavitha appeared before ED on Monday after the federal agency on March 16, issued a fresh summon to the BRS leader to join its ongoing inve...

Speaking at the inaugural session of the Global Investors Summit 2023 being held here, Jagan Mohan Reddy said the investment proposals are ...

"Further to the disclosure of even date, the company further learnt that the arrest of P Sarath Chandra Reddy, whole-time director/promoter...

Aurobindo Pharma is understood to have shortlisted four bulge-bracket global investors - Blackstone Group, Advent International, CVC Capita...

"The percentage of shareholding in the joint venture company will be 30 per cent and 70 per cent between Helix and Luoxin," Aurobindo Pharm...

The acquired business has been carved out by the management of Sandoz for divestment.

Plethico USA had not fulfilled obligations while selling Natrol to Aurobindo Pharma USA, hence they have to pay a penalty.

Drug firm Aurobindo Pharma today said its consolidated net profit rose by 9.81 per cent to Rs 188.63 crore for the third quarter ended Dece...

From being a low-margin pharma manufacturer, Aurobindo Pharma is transforming itself into a high-margin formulations player.

Generic drugmaker Aurobindo Pharma has decided to divest its stake in loss-making Chinese subsidiary , Aurobindo (Datong) Bio Pharma (ADBPL...